caspofungin + voriconazole

A combination therapy of **caspofungin** and **voriconazole**, two antifungal agents with distinct mechanisms of action, used primarily for the treatment of invasive fungal infections, especially invasive aspergillosis and serious infections in immunocompromised or critically ill patients. **Caspofungin** is an echinocandin that inhibits the synthesis of β-1,3-D-glucan, an essential component of the fungal cell wall, leading to cell lysis. **Voriconazole** is a triazole antifungal that inhibits fungal cytochrome P450-dependent 14-α-demethylase, disrupting ergosterol synthesis and fungal cell membrane integrity. Combination therapy may offer slight improvements in fungal burden reduction or survival in certain models compared to monotherapy, though studies in humans show no significant superiority over monotherapy and potentially increased risk of some adverse effects such as pancytopenia. Indicated primarily in severe, refractory, or high-risk invasive fungal infection settings, especially in immunocompromised patients, or where monotherapy is unsatisfactory[1][3][5].